Loading company…
Oxford-based provider of technologies for cell and gene therapy production, acquired by WuXi AppTec Group in March 2021.
Founded in 2011 and based in Oxford, UK, OXGENE develops technologies such as XOFLX, TESSA and SnapFast plasmids to improve the production of viral vectors for cell and gene therapies. In March 2021 the company was acquired by WuXi AppTec Group for EUR 111.6 million. OXGENE has engaged in a total of 7 deals since its inception.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in